Which has stronger valuation & earnings, AMGN or AZN?

Astrazeneca has higher revenue and earnings than Amgen. Amgen is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Amgen $36.75B 5.26 $7.71B $14.37 24.94 Astrazeneca $58.74B 4.44 $10.23B $6.66 25.27

Is AMGN or AZN more profitable?

Amgen has a net margin of 20.96% compared to Astrazeneca's net margin of 17.19%. Amgen's return on equity of 137.41% beat Astrazeneca's return on equity. Company Net Margins Return on Equity Return on Assets Amgen 20.96% 137.41% 13.28% Astrazeneca 17.19% 30.86% 12.68%

Does the media favor AMGN or AZN?

In the previous week, Astrazeneca had 31 more articles in the media than Amgen. MarketBeat recorded 65 mentions for Astrazeneca and 34 mentions for Amgen. Amgen's average media sentiment score of 1.33 beat Astrazeneca's score of 0.47 indicating that Amgen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amgen 27 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Astrazeneca 36 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 10 Negative mention(s) 8 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, BIIB or AZN?

Astrazeneca has higher revenue and earnings than Biogen. Biogen is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biogen $9.89B 2.94 $1.29B $9.32 21.16 Astrazeneca $58.74B 4.44 $10.23B $6.66 25.27

Is BIIB or AZN more profitable?

Astrazeneca has a net margin of 17.19% compared to Biogen's net margin of 13.81%. Astrazeneca's return on equity of 30.86% beat Biogen's return on equity. Company Net Margins Return on Equity Return on Assets Biogen 13.81% 12.83% 8.01% Astrazeneca 17.19% 30.86% 12.68%

Does the media refer more to BIIB or AZN?

In the previous week, Astrazeneca had 6 more articles in the media than Biogen. MarketBeat recorded 65 mentions for Astrazeneca and 59 mentions for Biogen. Biogen's average media sentiment score of 0.78 beat Astrazeneca's score of 0.47 indicating that Biogen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 29 Very Positive mention(s) 8 Positive mention(s) 12 Neutral mention(s) 7 Negative mention(s) 1 Very Negative mention(s) Positive Astrazeneca 36 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 10 Negative mention(s) 8 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, MRNA or AZN?

Astrazeneca has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Moderna $2.20B 12.29 -$2.82B -$8.15 N/A Astrazeneca $58.74B 4.44 $10.23B $6.66 25.27

Is MRNA or AZN more profitable?

Astrazeneca has a net margin of 17.19% compared to Moderna's net margin of -143.55%. Astrazeneca's return on equity of 30.86% beat Moderna's return on equity. Company Net Margins Return on Equity Return on Assets Moderna -143.55% -26.64% -19.32% Astrazeneca 17.19% 30.86% 12.68%

Does the media refer more to MRNA or AZN?

In the previous week, Astrazeneca had 45 more articles in the media than Moderna. MarketBeat recorded 65 mentions for Astrazeneca and 20 mentions for Moderna. Moderna's average media sentiment score of 0.72 beat Astrazeneca's score of 0.47 indicating that Moderna is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 7 Very Positive mention(s) 5 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Astrazeneca 36 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 10 Negative mention(s) 8 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, NVAX or AZN?

Astrazeneca has higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novavax $1.12B 1.23 $440.30M -$0.58 N/A Astrazeneca $58.74B 4.44 $10.23B $6.66 25.27

Is NVAX or AZN more profitable?

Astrazeneca has a net margin of 17.19% compared to Novavax's net margin of -14.73%. Astrazeneca's return on equity of 30.86% beat Novavax's return on equity. Company Net Margins Return on Equity Return on Assets Novavax -14.73% -14.82% 1.23% Astrazeneca 17.19% 30.86% 12.68%

Does the media refer more to NVAX or AZN?

In the previous week, Astrazeneca had 51 more articles in the media than Novavax. MarketBeat recorded 65 mentions for Astrazeneca and 14 mentions for Novavax. Novavax's average media sentiment score of 0.88 beat Astrazeneca's score of 0.47 indicating that Novavax is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novavax 7 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Astrazeneca 36 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 10 Negative mention(s) 8 Very Negative mention(s) Neutral

Which has better valuation & earnings, ABBV or AZN?

Astrazeneca has lower revenue, but higher earnings than AbbVie. Astrazeneca is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AbbVie $61.16B 7.05 $4.23B $2.03 120.30 Astrazeneca $58.74B 4.44 $10.23B $6.66 25.27

Is ABBV or AZN more profitable?

Astrazeneca has a net margin of 17.19% compared to AbbVie's net margin of 5.79%. Astrazeneca's return on equity of 30.86% beat AbbVie's return on equity. Company Net Margins Return on Equity Return on Assets AbbVie 5.79% -576.45% 13.39% Astrazeneca 17.19% 30.86% 12.68%

Does the media refer more to ABBV or AZN?

In the previous week, Astrazeneca had 8 more articles in the media than AbbVie. MarketBeat recorded 65 mentions for Astrazeneca and 57 mentions for AbbVie. AbbVie's average media sentiment score of 1.16 beat Astrazeneca's score of 0.47 indicating that AbbVie is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AbbVie 40 Very Positive mention(s) 5 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Astrazeneca 36 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 10 Negative mention(s) 8 Very Negative mention(s) Neutral

Astrazeneca (AZN) Competitors

$168.27 +3.77 (+2.29%)

Closing price 07/15/2026 03:59 PM Eastern

Extended Trading

$165.21 -3.06 (-1.82%)

As of 07/15/2026 07:52 PM Eastern

Compare

AZN vs. AMGN, BIIB, MRNA, NVAX, and ABBV

Should you buy Astrazeneca stock or one of its competitors? MarketBeat compares Astrazeneca with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Astrazeneca include Amgen (AMGN), Biogen (BIIB), Moderna (MRNA), Novavax (NVAX), and AbbVie (ABBV).

How does Astrazeneca compare to Amgen?

Amgen (NASDAQ:AMGN) and Astrazeneca (NYSE:AZN) are related large-cap companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and risk.

In the previous week, Astrazeneca had 31 more articles in the media than Amgen. MarketBeat recorded 65 mentions for Astrazeneca and 34 mentions for Amgen. Amgen's average media sentiment score of 1.33 beat Astrazeneca's score of 0.47 indicating that Amgen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amgen	27 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Astrazeneca	36 Very Positive mention(s)	4 Positive mention(s)	7 Neutral mention(s)	10 Negative mention(s)	8 Very Negative mention(s)	Neutral

Amgen has a beta of 0.41, indicating that its stock price is 59% less volatile than the broader market. Comparatively, Astrazeneca has a beta of 0.24, indicating that its stock price is 76% less volatile than the broader market.

76.5% of Amgen shares are held by institutional investors. Comparatively, 20.4% of Astrazeneca shares are held by institutional investors. 0.9% of Amgen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Amgen pays an annual dividend of $10.08 per share and has a dividend yield of 2.8%. Astrazeneca pays an annual dividend of $4.34 per share and has a dividend yield of 2.6%. Amgen pays out 70.1% of its earnings in the form of a dividend. Astrazeneca pays out 65.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Amgen has increased its dividend for 14 consecutive years. Amgen is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Amgen currently has a consensus target price of $356.62, indicating a potential downside of 0.48%. Astrazeneca has a consensus target price of $211.00, indicating a potential upside of 25.40%. Given Astrazeneca's stronger consensus rating and higher probable upside, analysts clearly believe Astrazeneca is more favorable than Amgen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amgen	2 Sell rating(s)	15 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.43
Astrazeneca	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

Amgen has a net margin of 20.96% compared to Astrazeneca's net margin of 17.19%. Amgen's return on equity of 137.41% beat Astrazeneca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amgen	20.96%	137.41%	13.28%
Astrazeneca	17.19%	30.86%	12.68%

Astrazeneca has higher revenue and earnings than Amgen. Amgen is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amgen	$36.75B	5.26	$7.71B	$14.37	24.94
Astrazeneca	$58.74B	4.44	$10.23B	$6.66	25.27

Summary

Amgen beats Astrazeneca on 12 of the 20 factors compared between the two stocks.

How does Astrazeneca compare to Biogen?

Biogen (NASDAQ:BIIB) and Astrazeneca (NYSE:AZN) are related large-cap companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, media sentiment, analyst recommendations, institutional ownership and profitability.

87.9% of Biogen shares are held by institutional investors. Comparatively, 20.4% of Astrazeneca shares are held by institutional investors. 0.3% of Biogen shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Astrazeneca has a net margin of 17.19% compared to Biogen's net margin of 13.81%. Astrazeneca's return on equity of 30.86% beat Biogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	13.81%	12.83%	8.01%
Astrazeneca	17.19%	30.86%	12.68%

Biogen currently has a consensus target price of $220.04, suggesting a potential upside of 11.56%. Astrazeneca has a consensus target price of $211.00, suggesting a potential upside of 25.40%. Given Astrazeneca's stronger consensus rating and higher possible upside, analysts plainly believe Astrazeneca is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	2 Sell rating(s)	11 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.55
Astrazeneca	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

In the previous week, Astrazeneca had 6 more articles in the media than Biogen. MarketBeat recorded 65 mentions for Astrazeneca and 59 mentions for Biogen. Biogen's average media sentiment score of 0.78 beat Astrazeneca's score of 0.47 indicating that Biogen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biogen	29 Very Positive mention(s)	8 Positive mention(s)	12 Neutral mention(s)	7 Negative mention(s)	1 Very Negative mention(s)	Positive
Astrazeneca	36 Very Positive mention(s)	4 Positive mention(s)	7 Neutral mention(s)	10 Negative mention(s)	8 Very Negative mention(s)	Neutral

Biogen has a beta of 0.16, suggesting that its stock price is 84% less volatile than the broader market. Comparatively, Astrazeneca has a beta of 0.24, suggesting that its stock price is 76% less volatile than the broader market.

Astrazeneca has higher revenue and earnings than Biogen. Biogen is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$9.89B	2.94	$1.29B	$9.32	21.16
Astrazeneca	$58.74B	4.44	$10.23B	$6.66	25.27

Summary

Astrazeneca beats Biogen on 11 of the 17 factors compared between the two stocks.

How does Astrazeneca compare to Moderna?

Moderna (NASDAQ:MRNA) and Astrazeneca (NYSE:AZN) are both large-cap pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, media sentiment, valuation, earnings, analyst recommendations, institutional ownership and profitability.

75.3% of Moderna shares are held by institutional investors. Comparatively, 20.4% of Astrazeneca shares are held by institutional investors. 10.8% of Moderna shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Moderna has a beta of 0.94, meaning that its share price is 6% less volatile than the broader market. Comparatively, Astrazeneca has a beta of 0.24, meaning that its share price is 76% less volatile than the broader market.

Moderna presently has a consensus price target of $38.27, suggesting a potential downside of 43.96%. Astrazeneca has a consensus price target of $211.00, suggesting a potential upside of 25.40%. Given Astrazeneca's stronger consensus rating and higher probable upside, analysts clearly believe Astrazeneca is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	10 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.82
Astrazeneca	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

Astrazeneca has a net margin of 17.19% compared to Moderna's net margin of -143.55%. Astrazeneca's return on equity of 30.86% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-143.55%	-26.64%	-19.32%
Astrazeneca	17.19%	30.86%	12.68%

Astrazeneca has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$2.20B	12.29	-$2.82B	-$8.15	N/A
Astrazeneca	$58.74B	4.44	$10.23B	$6.66	25.27

In the previous week, Astrazeneca had 45 more articles in the media than Moderna. MarketBeat recorded 65 mentions for Astrazeneca and 20 mentions for Moderna. Moderna's average media sentiment score of 0.72 beat Astrazeneca's score of 0.47 indicating that Moderna is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	7 Very Positive mention(s)	5 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Astrazeneca	36 Very Positive mention(s)	4 Positive mention(s)	7 Neutral mention(s)	10 Negative mention(s)	8 Very Negative mention(s)	Neutral

Summary

Astrazeneca beats Moderna on 11 of the 16 factors compared between the two stocks.

How does Astrazeneca compare to Novavax?

Novavax (NASDAQ:NVAX) and Astrazeneca (NYSE:AZN) are related companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, media sentiment, valuation, analyst recommendations, risk and institutional ownership.

Astrazeneca has a net margin of 17.19% compared to Novavax's net margin of -14.73%. Astrazeneca's return on equity of 30.86% beat Novavax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novavax	-14.73%	-14.82%	1.23%
Astrazeneca	17.19%	30.86%	12.68%

53.0% of Novavax shares are held by institutional investors. Comparatively, 20.4% of Astrazeneca shares are held by institutional investors. 1.6% of Novavax shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Astrazeneca had 51 more articles in the media than Novavax. MarketBeat recorded 65 mentions for Astrazeneca and 14 mentions for Novavax. Novavax's average media sentiment score of 0.88 beat Astrazeneca's score of 0.47 indicating that Novavax is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novavax	7 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Astrazeneca	36 Very Positive mention(s)	4 Positive mention(s)	7 Neutral mention(s)	10 Negative mention(s)	8 Very Negative mention(s)	Neutral

Novavax presently has a consensus target price of $13.00, suggesting a potential upside of 54.21%. Astrazeneca has a consensus target price of $211.00, suggesting a potential upside of 25.40%. Given Novavax's higher possible upside, equities research analysts clearly believe Novavax is more favorable than Astrazeneca.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novavax	3 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.40
Astrazeneca	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

Astrazeneca has higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novavax	$1.12B	1.23	$440.30M	-$0.58	N/A
Astrazeneca	$58.74B	4.44	$10.23B	$6.66	25.27

Novavax has a beta of 2.43, meaning that its stock price is 143% more volatile than the broader market. Comparatively, Astrazeneca has a beta of 0.24, meaning that its stock price is 76% less volatile than the broader market.

Summary

Astrazeneca beats Novavax on 11 of the 17 factors compared between the two stocks.

How does Astrazeneca compare to AbbVie?

AbbVie (NYSE:ABBV) and Astrazeneca (NYSE:AZN) are related large-cap companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, media sentiment, earnings and valuation.

In the previous week, Astrazeneca had 8 more articles in the media than AbbVie. MarketBeat recorded 65 mentions for Astrazeneca and 57 mentions for AbbVie. AbbVie's average media sentiment score of 1.16 beat Astrazeneca's score of 0.47 indicating that AbbVie is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AbbVie	40 Very Positive mention(s)	5 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Astrazeneca	36 Very Positive mention(s)	4 Positive mention(s)	7 Neutral mention(s)	10 Negative mention(s)	8 Very Negative mention(s)	Neutral

AbbVie currently has a consensus price target of $267.67, indicating a potential upside of 9.61%. Astrazeneca has a consensus price target of $211.00, indicating a potential upside of 25.40%. Given Astrazeneca's higher probable upside, analysts clearly believe Astrazeneca is more favorable than AbbVie.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbbVie	0 Sell rating(s)	6 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.84
Astrazeneca	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

Astrazeneca has lower revenue, but higher earnings than AbbVie. Astrazeneca is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbbVie	$61.16B	7.05	$4.23B	$2.03	120.30
Astrazeneca	$58.74B	4.44	$10.23B	$6.66	25.27

AbbVie has a beta of 0.3, meaning that its share price is 70% less volatile than the broader market. Comparatively, Astrazeneca has a beta of 0.24, meaning that its share price is 76% less volatile than the broader market.

70.2% of AbbVie shares are owned by institutional investors. Comparatively, 20.4% of Astrazeneca shares are owned by institutional investors. 0.1% of AbbVie shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

AbbVie pays an annual dividend of $6.92 per share and has a dividend yield of 2.8%. Astrazeneca pays an annual dividend of $4.34 per share and has a dividend yield of 2.6%. AbbVie pays out 340.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Astrazeneca pays out 65.2% of its earnings in the form of a dividend. AbbVie has increased its dividend for 53 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Astrazeneca has a net margin of 17.19% compared to AbbVie's net margin of 5.79%. Astrazeneca's return on equity of 30.86% beat AbbVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbbVie	5.79%	-576.45%	13.39%
Astrazeneca	17.19%	30.86%	12.68%

Summary

AbbVie beats Astrazeneca on 13 of the 20 factors compared between the two stocks.

Get Astrazeneca News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AZN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AZN vs. The Competition

Export

Metric	Astrazeneca	Industry	Manufacturing Sector	NYSE Exchange
Market Cap	$255.12B	$3.15B	$4.37B	$23.40B
Dividend Yield	2.64%	15.22%	38.37%	4.01%
P/E Ratio	25.27	13.27	23.69	31.19
Price / Sales	4.44	2,726.14	140.82	79.72
Price / Cash	12.72	25.97	165.68	32.25
Price / Book	5.36	8.75	12.18	4.78
Net Income	$10.23B	-$34.05M	$120.20M	$1.07B
7 Day Performance	-5.71%	0.54%	-1.35%	0.52%
1 Month Performance	-5.89%	-0.11%	-2.29%	0.54%
1 Year Performance	20.05%	11.84%	10.98%	18.39%

Astrazeneca Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AZN Astrazeneca	4.6205 of 5 stars	$168.27 +2.3%	$211.00 +25.4%	+19.6%	$255.12B	$58.74B	25.27	96,100	Trending News Analyst Downgrade
AMGN Amgen	4.029 of 5 stars	$363.39 -0.1%	$355.73 -2.1%	+22.5%	$196.13B	$36.75B	25.29	31,500	Positive News Analyst Forecast
BIIB Biogen	3.8397 of 5 stars	$199.15 +0.1%	$218.15 +9.5%	+54.7%	$29.40B	$9.89B	21.37	7,500	Trending News Analyst Upgrade
MRNA Moderna	1.8321 of 5 stars	$68.27 -10.8%	$38.27 -43.9%	+116.2%	$27.09B	$1.94B	N/A	4,700
NVAX Novavax	2.1936 of 5 stars	$9.33 -0.7%	$13.00 +39.3%	+22.5%	$1.53B	$596.34M	N/A	1,990

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:AZN) was last updated on 7/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Astrazeneca (AZN) Competitors